Molecular markers (c-erbB-2, p53) in breast cancer

被引:10
作者
Agrawal, Anil Kumar [1 ]
Jelen, Michal [2 ]
Rudnicki, Jerzy [1 ]
Grzebieniak, Zygmunt [1 ]
Zukrowski, Piotr [1 ]
Nienartowicz, Ewa [3 ]
机构
[1] Wroclaw Med Univ, Dept Gen & Oncol Surg 2, Wroclaw, Poland
[2] Wroclaw Med Univ, Dept Pathol, Wroclaw, Poland
[3] Wroclaw Med Univ, Dept Radiol, Wroclaw, Poland
关键词
breast cancer; molecular markers; p53; c-erbB-2;
D O I
10.2478/v10042-008-0059-7
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The aim of our study was to evaluate the correlation between clinical characteristics, histopatologic features and c-erbB-2 as well as p53 expression in cancer tissues. Breast cancer tissue was obtained from 184 female subjects with primary breast cancer. According to hormonal status patients were divided into two groups - 64 belonged to the premenopausal group and 120 to postmenopausal group. Each patient underwent mammectomy and axillary lymphadenectomy. c-erbB-2 protooncogene was detected in 54% cases, and was correlated with infiltrating type of cancer growth, as well as larger tumor size. The presence of p53 antioncogene was observed only in 33% of cases, mainly in infiltrating duct carcinomas. The incidence of c-erbB-2 and p53 positive cases was higher among subjects, whose ultrasound and mammography revealed malignancy. There was no correlation found between of c-erbB-2 expression and axillary lymph nodes involvement It seems probable, that c-erbB-2 and p53 status of cancer tissue may prove to be useful in assessment of the level of biological aggressiveness in breast carcinomas and hence can be used as a prognostic factor.
引用
收藏
页码:449 / 455
页数:7
相关论文
共 55 条
[1]   Association between mammographic breast density and breast cancer tumor characteristics [J].
Aiello, EJ ;
Buist, DSM ;
Emily, W ;
Porter, PL .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2005, 14 (03) :662-668
[2]   AMPLIFICATION OF C-ERBB-2 AND AGGRESSIVE HUMAN-BREAST TUMORS [J].
ALI, IU ;
CAMPBELL, G ;
LIDEREAU, R ;
CALLAHAN, R .
SCIENCE, 1988, 240 (4860) :1795-1796
[3]   Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome [J].
Arpino, G ;
Bardou, VJ ;
Clark, GM ;
Elledge, RM .
BREAST CANCER RESEARCH, 2004, 6 (03) :R149-R156
[4]   ABNORMAL EXPRESSION OF WILD TYPE-P53 PROTEIN IN NORMAL-CELLS OF A CANCER FAMILY PATIENT [J].
BARNES, DM ;
HANBY, AM ;
GILLETT, CE ;
MOHAMMED, S ;
HODGSON, S ;
BOBROW, LG ;
LEIGH, IM ;
PURKIS, T ;
MACGEOCH, C ;
SPURR, NK ;
BARTEK, J ;
VOJTESEK, B ;
PICKSLEY, SM ;
LANE, DP .
LANCET, 1992, 340 (8814) :259-263
[5]   PATTERNS OF EXPRESSION OF THE P53 TUMOR SUPPRESSOR IN HUMAN BREAST TISSUES AND TUMORS INSITU AND INVITRO [J].
BARTEK, J ;
BARTKOVA, J ;
VOJTESEK, B ;
STASKOVA, Z ;
REJTHAR, A ;
KOVARIK, J ;
LANE, DP .
INTERNATIONAL JOURNAL OF CANCER, 1990, 46 (05) :839-844
[6]  
BERGER MS, 1988, CANCER RES, V48, P1238
[7]  
BOKINIECDZIEWUL.A, 1994, NOWOTWORY, V44, P310
[8]   The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer [J].
Bull, SB ;
Ozcelik, H ;
Pinnaduwage, D ;
Blackstein, ME ;
Sutherland, DAJ ;
Pritchard, KI ;
Tzontcheva, AT ;
Sidlofsky, S ;
Hanna, WM ;
Qizilbash, AH ;
Tweeddale, ME ;
Fine, S ;
McCready, DR ;
Andrulis, IL .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (01) :86-96
[9]   GENETIC ALTERATIONS IN PRIMARY BREAST-CANCER [J].
CALLAHAN, R .
BREAST CANCER RESEARCH AND TREATMENT, 1989, 13 (03) :191-203
[10]   P53 EXPRESSION IN BREAST-CANCER [J].
CATTORETTI, G ;
RILKE, F ;
ANDREOLA, S ;
DAMATO, L ;
DELIA, D .
INTERNATIONAL JOURNAL OF CANCER, 1988, 41 (02) :178-183